LPCN vs. EYEN, VAXX, ITRM, UBX, SNSE, DRRX, QLI, ENLV, SLGL, and FBRX
Should you be buying Lipocine stock or one of its competitors? The main competitors of Lipocine include Eyenovia (EYEN), Vaxxinity (VAXX), Iterum Therapeutics (ITRM), Unity Biotechnology (UBX), Sensei Biotherapeutics (SNSE), DURECT (DRRX), Qilian International Holding Group (QLI), Enlivex Therapeutics (ENLV), Sol-Gel Technologies (SLGL), and Forte Biosciences (FBRX). These companies are all part of the "pharmaceutical preparations" industry.
Lipocine (NASDAQ:LPCN) and Eyenovia (NASDAQ:EYEN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, community ranking, media sentiment, risk, dividends and valuation.
Lipocine has higher revenue and earnings than Eyenovia. Lipocine is trading at a lower price-to-earnings ratio than Eyenovia, indicating that it is currently the more affordable of the two stocks.
Lipocine has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500. Comparatively, Eyenovia has a beta of 1.71, meaning that its stock price is 71% more volatile than the S&P 500.
Lipocine received 174 more outperform votes than Eyenovia when rated by MarketBeat users. Likewise, 70.43% of users gave Lipocine an outperform vote while only 65.00% of users gave Eyenovia an outperform vote.
9.1% of Lipocine shares are owned by institutional investors. Comparatively, 25.8% of Eyenovia shares are owned by institutional investors. 5.0% of Lipocine shares are owned by company insiders. Comparatively, 7.8% of Eyenovia shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Eyenovia has a consensus target price of $10.00, indicating a potential upside of 866.18%. Given Eyenovia's higher probable upside, analysts plainly believe Eyenovia is more favorable than Lipocine.
In the previous week, Lipocine had 2 more articles in the media than Eyenovia. MarketBeat recorded 2 mentions for Lipocine and 0 mentions for Eyenovia. Lipocine's average media sentiment score of 0.00 equaled Eyenovia'saverage media sentiment score.
Lipocine's return on equity of -63.28% beat Eyenovia's return on equity.
Summary
Lipocine and Eyenovia tied by winning 7 of the 14 factors compared between the two stocks.
Get Lipocine News Delivered to You Automatically
Sign up to receive the latest news and ratings for LPCN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LPCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lipocine Competitors List
Related Companies and Tools
